Cardiac Glycoside Plant Poisoning Medication

  • Author: Raffi Kapitanyan, MD; Chief Editor: Asim Tarabar, MD   more...
 
Updated: May 10, 2011
 

Medication Summary

Categories of drugs used to manage cardiac glycoside plant toxicity include drugs to minimize absorption and increase excretion, drugs that lower extracellular potassium, antidysrhythmics, and antidotes (eg, digoxin Fab fragments).

Next

GI decontaminants

Class Summary

Activated charcoal is used to bind toxin within the GI tract. Due to enterohepatic/enteroenteric recirculation of cardiac glycosides, multiple doses can be given to help enhance elimination.

Activated charcoal (Liqui-Char)

 

Emergency treatment in poisoning caused by drugs and chemicals. Network of pores present in activated charcoal adsorbs 100-1000 mg of drug per gram of charcoal. Does not dissolve in water.

For maximum effect, administer within 30 min after ingesting poison. First dose may be given with a cathartic (eg, sorbitol); subsequent doses should be given without a cathartic, as often as q2-6h, and should not be given in presence of ileus.

Previous
Next

Antihyperkalemics

Class Summary

Hyperkalemia usually results from acute overdose and represents redistribution of potassium from intracellular to extracellular compartment; therefore, drugs of choice include agents that promote potassium redistribution from extracellular to intracellular compartments. Avoid calcium, as it may exacerbate effects of cardiac glycosides and may promote rhythm deterioration when used in this context.

Glucose (D50W) and insulin (Humulin R, Novolin R)

 

Redistributes potassium intracellularly; onset of action is 30 min and duration of action is 4-6h.

Used for life-threatening hyperkalemia (>6.5 mEq/L). Use cautiously with digoxin Fab as profound hypokalemia may occur.

Observe serum glucose level and administer additional D50W if needed

Sodium bicarbonate (Neut)

 

Sodium counteracts potassium effects, while alkalosis created by bicarbonate leads to a redistribution of potassium intracellularly. Onset of action is 5-10 min and duration of action is 1-2 h.

Used for life-threatening hyperkalemia (>6.5 mEq/L). Use cautiously with digoxin Fab as profound hypokalemia may occur.

Previous
Next

Antiarrhythmic agents

Class Summary

Used to treat variety of bradydysrhythmias and tachydysrhythmias occurring with cardiac glycoside toxicity.

Atropine IV/IM (Atropisol)

 

Used for bradycardia and conduction blocks in standard ACLS doses.

Doses < 0.1 mg in children or 0.5 mg in adults may lead to paradoxical bradycardia.

Phenytoin (Dilantin)

 

Useful for ventricular dysrhythmias, such as V-fib, V-tach, and PVCs. DOC for cardiac glycoside-induced tachydysrhythmias. Only antidysrhythmic which stabilizes myocardium and improves conduction through AV node.

Monitor serum phenytoin levels closely to assure therapeutic levels of 10-20 mcg/mL.

Lidocaine (Xylocaine)

 

Class IB antiarrhythmic that increases electrical stimulation threshold of the ventricle, suppressing automaticity of conduction through the tissue.

Magnesium sulfate

 

Nutritional supplement in hyperalimentation; cofactor in enzyme systems involved in neurochemical transmission and muscular excitability.

In adults, 60-180 mEq of potassium, 10-30 mEq of magnesium, and 10-40 mmol/L of phosphate per day may be necessary for optimum metabolic response.

Although serum magnesium levels may be normal, existence of intracellular hypomagnesemia has been hypothesized; therefore, magnesium may be beneficial.

Previous
Next

Antidote

Class Summary

Sheep-derived IgG antibodies to digoxin have been used successfully in patients with oleander toxicity. They cross-react with other cardiac glycosides and may be helpful in certain situations, including hyperkalemia not quickly responsive to standard treatments, life-threatening dysrhythmias not quickly responsive to standard treatments, and cardiac arrest.

Digoxin Fab fragments (Digibind)

 

Because serum digoxin/digitoxin levels do not reflect ingested amount of plant cardiac glycoside, drug levels should not be used to calculate Fab dose. Elevated levels of digoxin or digitoxin only confirm exposure. Undetectable level of serum cardiac glycosides does not rule out exposure. Elevated serum potassium would be a useful indicator when considering this agent.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Raffi Kapitanyan, MD  Assistant Professor of Emergency Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School

Raffi Kapitanyan, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Mark Su, MD, FACEP, FACMT  Consulting Staff and Director of Fellowship in Medical Toxicology, Department of Emergency Medicine, North Shore University Hospital; Consulting Staff, North Shore University Hospital

Mark Su, MD, FACEP, FACMT is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Douglas R Landry, MD  Consulting Staff, Department of Emergency Medicine, Sentara Bayside Hospital

Douglas R Landry, MD is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

Specialty Editor Board

B Zane Horowitz, MD, FACMT  Professor, Department of Emergency Medicine, Oregon Health and Sciences University; Medical Director, Oregon Poison Center; Medical Director, Alaska Poison Control System

B Zane Horowitz, MD, FACMT is a member of the following medical societies: American Academy of Clinical Toxicology and American College of Medical Toxicology

Disclosure: Nothing to disclose.

John T VanDeVoort, PharmD  Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

Michael Hodgman, MD  Assistant Clinical Professor of Medicine, Department of Emergency Medicine, Bassett Healthcare

Michael Hodgman, MD is a member of the following medical societies: American College of Medical Toxicology, American College of Physicians, Medical Society of the State of New York, and Wilderness Medical Society

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Asim Tarabar, MD  Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure: Nothing to disclose.

References
  1. Bessen HA. Therapeutic and toxic effects of digitalis: William Withering, 1785. J Emerg Med. 1986;4(3):243-8. [Medline].

  2. Bronstein, AC, Spyker, DA, Cantilena Jr., LR, et al. 2006 annual report of the American Association of Poison Control Centers National Poison Data System. Clinical Toxicology. Dec 2007;45(8):815-917.

  3. Eddleston M, Ariaratnam CA, Sjostrom L, Jayalath S, Rajakanthan K, Rajapakse S. Acute yellow oleander (Thevetia peruviana) poisoning: cardiac arrhythmias, electrolyte disturbances, and serum cardiac glycoside concentrations on presentation to hospital. Heart. Mar 2000;83(3):301-6. [Medline].

  4. Gowda RM, Cohen RA, Khan IA. Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications. Heart. Apr 2003;89(4):e14. [Medline].

  5. Hack JB, Woody JH, Lewis DE, et al. The effect of calcium chloride in treating hyperkalemia due to acute digoxin toxicity in a porcine model. J Toxicol Clin Toxicol. 2004;42(4):337-42. [Medline].

  6. Roberts DM, Buckley NA. Antidotes for acute cardenolide (cardiac glycoside) poisoning. Cochrane Database Syst Rev. Oct 18 2006;CD005490. [Medline].

  7. Bain RJ. Accidental digitalis poisoning due to drinking herbal tea. Br Med J (Clin Res Ed). Jun 1 1985;290(6482):1624. [Medline].

  8. Cheung K, Urech R, Taylor L. Plant cardiac glycosides and digoxin Fab antibody. J Paediatr Child Health. Oct 1991;27(5):312-3. [Medline].

  9. Dickstein ES, Kunkel FW. Foxglove tea poisoning. Am J Med. Jul 1980;69(1):167-9. [Medline].

  10. Eddleston M, Rajapakse S, Rajakanthan, Jayalath S, Sjostrom L, Santharaj W. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet. Mar 18 2000;355(9208):967-72. [Medline].

  11. el Bahri L, Djegham M, Makhlouf M. Urginea maritima L (Squill): a poisonous plant of North Africa. Vet Hum Toxicol. Apr 2000;42(2):108-10. [Medline].

  12. Furbee B, Wermuth M. Life-threatening plant poisoning. Crit Care Clin. Oct 1997;13(4):849-88. [Medline].

  13. Goldfrank, Flomenbaum, Lewin, et al. Cardiac glycosides. In: Goldfrank's Toxicologic Emergencies. 7th ed. 2002:724-734.

  14. Rich SA, Libera JM, Locke RJ. Treatment of foxglove extract poisoning with digoxin-specific Fab fragments. Ann Emerg Med. Dec 1993;22(12):1904-7. [Medline].

  15. Plants - cardiac glycosides. In: Rumack BH, ed. Poisondex. 1997:94.

  16. Slifman NR, Obermeyer WR, Aloi BK, Musser SM, Correll WA Jr, Cichowicz SM. Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med. Sep 17 1998;339(12):806-11. [Medline].

  17. Van Deusen SK, Birkhahn RH, Gaeta TJ. Treatment of hyperkalemia in a patient with unrecognized digitalis toxicity. J Toxicol Clin Toxicol. 2003;41(4):373-6. [Medline].

Previous
Next
 
The plant shown is foxglove (Digitalis purpura), which contains cardiac glycosides, not tropane alkaloids. © 2000 Richard Wagner
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.